Free Trial
NASDAQ:SKYE

Skye Bioscience (SKYE) Stock Price, News & Analysis

Skye Bioscience logo
$3.50 +0.02 (+0.57%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$3.50 0.00 (0.00%)
As of 08/29/2025 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Skye Bioscience Stock (NASDAQ:SKYE)

Key Stats

Today's Range
$3.39
$3.61
50-Day Range
$3.14
$4.58
52-Week Range
$1.14
$7.11
Volume
159,367 shs
Average Volume
289,109 shs
Market Capitalization
$108.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50
Consensus Rating
Buy

Company Overview

Skye Bioscience Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
31st Percentile Overall Score

SKYE MarketRank™: 

Skye Bioscience scored higher than 31% of companies evaluated by MarketBeat, and ranked 792nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Skye Bioscience has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Skye Bioscience has only been the subject of 2 research reports in the past 90 days.

  • Read more about Skye Bioscience's stock forecast and price target.
  • Earnings Growth

    Earnings for Skye Bioscience are expected to decrease in the coming year, from ($1.04) to ($1.18) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Skye Bioscience is -3.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Skye Bioscience is -3.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Skye Bioscience has a P/B Ratio of 2.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    15.17% of the float of Skye Bioscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Skye Bioscience has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Skye Bioscience has recently increased by 1.12%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Skye Bioscience does not currently pay a dividend.

  • Dividend Growth

    Skye Bioscience does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.17% of the float of Skye Bioscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Skye Bioscience has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Skye Bioscience has recently increased by 1.12%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Skye Bioscience has a news sentiment score of -0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.05 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Skye Bioscience this week, compared to 3 articles on an average week.
  • Search Interest

    Only 7 people have searched for SKYE on MarketBeat in the last 30 days. This is a decrease of -59% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added Skye Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Skye Bioscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,601,097.00 in company stock.

  • Percentage Held by Insiders

    Only 4.50% of the stock of Skye Bioscience is held by insiders.

  • Percentage Held by Institutions

    Only 21.09% of the stock of Skye Bioscience is held by institutions.

  • Read more about Skye Bioscience's insider trading history.
Receive SKYE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Skye Bioscience and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SKYE Stock News Headlines

“Sell Nvidia before earnings”
Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.tc pixel
See More Headlines

SKYE Stock Analysis - Frequently Asked Questions

Skye Bioscience's stock was trading at $2.83 at the beginning of the year. Since then, SKYE stock has increased by 23.7% and is now trading at $3.50.

Skye Bioscience, Inc. (NASDAQ:SKYE) posted its quarterly earnings data on Thursday, August, 7th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.10.
Read the conference call transcript
.

Top institutional shareholders of Skye Bioscience include MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. (0.94%), Geode Capital Management LLC (0.65%), Marshall Wace LLP (0.34%) and Qube Research & Technologies Ltd (0.17%). Insiders that own company stock include Punit Dhillon, Paul A Grayson, Kaitlyn Arsenault, Tuan Tu Diep, Andrew J Schwab and 5Am Partners Vii, Llc.
View institutional ownership trends
.

Shares of SKYE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Skye Bioscience investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Alphabet (GOOG).

Company Calendar

Last Earnings
8/07/2025
Today
8/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SKYE
Previous Symbol
NASDAQ:SKYE
CIK
1516551
Fax
N/A
Employees
11
Year Founded
N/A

Price Target and Rating

High Price Target
$20.00
Low Price Target
$10.00
Potential Upside/Downside
+342.9%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.06)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$26.57 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-76.03%
Return on Assets
-69.20%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.09
Quick Ratio
6.09

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.41 per share
Price / Book
2.48

Miscellaneous

Outstanding Shares
30,990,000
Free Float
29,594,000
Market Cap
$108.47 million
Optionable
Optionable
Beta
2.21

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:SKYE) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners